<p>Data are raw numbers, percentages are in parentheses.</p><p>Abbreviations: PTMC, papillary thyroid microcarcinoma; PTC, papillary thyroid carcinoma.</p><p>* Numbers present the mean±standard deviation.</p><p>Association of the BRAF<sup>V600E</sup> mutation with clinicopathologic characteristics of patients with PTC.</p
An association between the BRAFV600E mutation and the clinicopathological progression of papillary t...
BACKGROUND: To evaluate the relationship between the BRAF V600E mutation and clinicopathologic param...
Introduction: BRAF(V600E) activating mutation is the most frequent genetic abnormality in the pathog...
<p>Data are raw numbers, percentages are in parentheses.</p><p>Abbreviations: PTMC, papillary thyroi...
Abstract CONTEXT: Because very few studies have examined the correlation between BRAF mutations an...
Background: The BRAF mutation has been shown to be associated with aggressive clinicopathologic char...
In this study, BRAF mutation was found in 219 of 500 cases (43.8%). In particular, we found the most...
Objective Papillary thyroid carcinoma (PTC) accounts for 95% of all thyroid carcinomas. PTC is an ep...
Abstract Background While some studies suggest that the BRAF V600E mutation correlates with a high-r...
Importance: BRAF V600E is a prominent oncogene in papillary thyroid cancer (PTC), but its role in PT...
Approximately 40% of papillary thyroid carcinomas (PTC) harbor the BRAF V600E mutation, which is sig...
ABSTRACT Objectives: We aimed to investigate the prevalence of the BRAF (V600E) mutation in consecu...
Context: Because very few studies have examined the correlation between BRAF mutations and clinicopa...
To correlate the presence of BRAF V600E mutation with clinicopathological parameters
Purpose To investigate the prognostic value of BRAF V600E mutation for the recurrence of papillary t...
An association between the BRAFV600E mutation and the clinicopathological progression of papillary t...
BACKGROUND: To evaluate the relationship between the BRAF V600E mutation and clinicopathologic param...
Introduction: BRAF(V600E) activating mutation is the most frequent genetic abnormality in the pathog...
<p>Data are raw numbers, percentages are in parentheses.</p><p>Abbreviations: PTMC, papillary thyroi...
Abstract CONTEXT: Because very few studies have examined the correlation between BRAF mutations an...
Background: The BRAF mutation has been shown to be associated with aggressive clinicopathologic char...
In this study, BRAF mutation was found in 219 of 500 cases (43.8%). In particular, we found the most...
Objective Papillary thyroid carcinoma (PTC) accounts for 95% of all thyroid carcinomas. PTC is an ep...
Abstract Background While some studies suggest that the BRAF V600E mutation correlates with a high-r...
Importance: BRAF V600E is a prominent oncogene in papillary thyroid cancer (PTC), but its role in PT...
Approximately 40% of papillary thyroid carcinomas (PTC) harbor the BRAF V600E mutation, which is sig...
ABSTRACT Objectives: We aimed to investigate the prevalence of the BRAF (V600E) mutation in consecu...
Context: Because very few studies have examined the correlation between BRAF mutations and clinicopa...
To correlate the presence of BRAF V600E mutation with clinicopathological parameters
Purpose To investigate the prognostic value of BRAF V600E mutation for the recurrence of papillary t...
An association between the BRAFV600E mutation and the clinicopathological progression of papillary t...
BACKGROUND: To evaluate the relationship between the BRAF V600E mutation and clinicopathologic param...
Introduction: BRAF(V600E) activating mutation is the most frequent genetic abnormality in the pathog...